XM does not provide services to residents of the United States of America.

Technical Analysis – GBPUSD pulls back from 15-month peak; bullish structure holds



GBPUSD has been in a prolonged uptrend since October 2022 supported by its long-term ascending trendline. Last Friday, the pair stormed to a fresh 15-month high of 1.3141 before paring some gains, but it is still too early to call this a downside correction.

However, the momentum indicators are holding well within their overbought territories, hinting that the recent pullback could extend. Specifically, the stochastic oscillator is negatively charged within its 80-overbought territory, while the RSI remains directionless in overbought conditions.

If the bears manage to push the price lower, the crucial 1.3000 psychological mark could act as the first line of defense. Sliding beneath that floor, the pair may face the previous resistance zone of 1.2847. Should that barricade fail also, the congested region that includes the ascending trendline taken from October 2022 and the 50-day simple moving average (SMA) could cap the pair’s downside before the June support of 1.2590 gets tested.

On the flipside, if the long-term bullish structure extends, the 15-month peak of 1.3141 might be the first hurdle for buyers to clear. Jumping to a fresh higher high, the pair could ascend towards the March 2022 resistance of 1.3297. A violation of the latter may open the door for the February 2022 resistance of 1.3436.

Overall, GBPUSD appears to be ready to experience a healthy correction due to reaching overbought conditions. Nevertheless, it is likely that the pair extends its bullish long-term structure as long as it holds above the ascending trendline.


Related Assets


Latest News

Technical Analysis – US 100 index hovers above cloud as rebound loses steam

U

Weekly Technical Outlook – EURUSD, GBPUSD, AUDUSD

E

Technical Analysis – Gold loses some ground but still bullish

G

G

Technical Analysis – AUDUSD remains undecided near crucial technical region

A

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.